GuangYuYuan(SH:600771)2024-05-21 10:28Group 1: Investor Relations and Brand Image - The company acknowledges the importance of utilizing shareholder resources and market attention to enhance brand and market image, encouraging interactions between mid-level management and shareholders to address issues [2][3] - The company is committed to maintaining open communication channels with shareholders to improve brand reputation and operational quality, ultimately benefiting all shareholders [3] Group 2: Market Performance and Shareholder Concerns - The company has over 60,000 small shareholders, many of whom have held shares since the state-owned enterprise took over in 2021, expressing concerns over stagnant stock prices and their long-term investments [3][4] - Management is aware of the secondary market trends and values shareholder feedback, emphasizing the importance of improving operational quality to regain shareholder trust [4][5] Group 3: Business Strategy and Product Development - The company does not have a fixed number of new store openings planned but focuses on the quality of new stores rather than quantity [4] - There are no current plans to launch an OTC version of the product "Gui Ling Ji" due to various policy restrictions, but the company will continue to monitor policy changes [4][5] Group 4: Financial Obligations and Compensation - The company has requested cash compensation of CNY 853.6397 million from Dongsheng Group and is actively communicating to ensure compliance with performance commitments [4][7] - If an agreement cannot be reached with Dongsheng Group, the company will pursue legal avenues to protect the interests of the company and its investors [7][8] Group 5: Marketing and Brand Promotion - The company recognizes its brand awareness is relatively low and plans to enhance marketing efforts through various channels, including cultural promotion and participation in industry events [5][6] - The company is focusing on a "Big Product +" strategy, emphasizing key products like "Gui Ling Ji" and expanding its product matrix to include health food categories [5][6] Group 6: Financial Management and Compliance - The company has undergone a thorough review of historical financial issues since relocating its headquarters back to Shanxi in 2022, addressing past discrepancies in revenue and expenses [6][7] - The company is committed to improving internal controls and financial disclosure quality to mitigate risks of delisting, ensuring compliance with regulatory requirements [18][19] Group 7: Future Outlook and Strategic Planning - The company plans to set revenue and profit targets based on its strategic direction of building a high-quality traditional Chinese medicine industry chain [19][20] - The company is exploring the introduction of professional management talent from the pharmaceutical sector to enhance its operational capabilities [12][13]